{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:58:48Z","timestamp":1792511928728,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The next pandemic may demand faster, more flexible responses with better risk-benefit and cost-benefit ratios than current systems can deliver. During COVID-19, R&amp;D funding allocation strongly favored vaccines over antivirals and regulatory approvals of vaccines far exceeded approvals for antivirals. Moreover, early evidence on antiviral effectiveness was often limited or even misleading. Antivirals may have advantages in early outbreak control, high-risk populations, and settings with delayed vaccine uptake. For future pandemics, we propose a dedicated antiviral agenda to coordinate R&amp;D for broad-spectrum agents, fund phase 2\/3 trials for high-severity pathogens, enable rapid manufacturing scale-up for demonstrably effective interventions, and secure equitable global access through tiered pricing, stockpiling, and technology transfer. This platform would fill the critical therapeutic blind spot in existing pandemic vaccine-centric strategies. The proposed approach should ensure transparency, strengthen equity, and provide rigorous evidence for both vaccines and antivirals, dissecting their relative benefits, limitations, complementarity, and cost\u2013benefit.<\/jats:p>","DOI":"10.1093\/cid\/ciaf648","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T12:55:43Z","timestamp":1763816143000},"page":"727-733","source":"Crossref","is-referenced-by-count":4,"title":["Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2697-0654","authenticated-orcid":false,"given":"Antonios-Periklis","family":"Panagiotopoulos","sequence":"first","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-9198","authenticated-orcid":false,"given":"Cleo","family":"Anastassopoulou","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0656-4715","authenticated-orcid":false,"given":"Athanasios","family":"Tsakris","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Medical School, National and Kapodistrian University of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-6859","authenticated-orcid":false,"given":"John P A","family":"Ioannidis","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Epidemiology and Population Health, and Biomedical Data Science, and Meta-Research Innovation Center at Stanford (METRICS), Stanford University , Stanford, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"2026043013120627800_ciaf648-B1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.healthpol.2022.04.004","article-title":"Lessons learned from the COVID-19 pandemic","volume":"126","author":"Van Ginneken","year":"2022","journal-title":"Health Policy"},{"key":"2026043013120627800_ciaf648-B2","doi-asserted-by":"crossref","first-page":"e02209","DOI":"10.1128\/jvi.02209-24","article-title":"Highly pathogenic avian influenza H5N1: history, current situation, and outlook","volume":"99","author":"Krammer","year":"2025","journal-title":"J Virol"},{"key":"2026043013120627800_ciaf648-B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/bmj.p434","article-title":"H5n1: governments should invest in vaccines for all flu strains, says incoming WHO chief scientist","volume":"380","author":"Mahase","year":"2023","journal-title":"BMJ"},{"key":"2026043013120627800_ciaf648-B4","doi-asserted-by":"crossref","first-page":"100549","DOI":"10.1016\/j.xcrm.2022.100549","article-title":"Antiviral agents for the treatment of COVID-19: progress and challenges","volume":"3","author":"Singh","year":"2022","journal-title":"Cell Rep Med"},{"key":"2026043013120627800_ciaf648-B5","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors","year":"2021","journal-title":"Nat Commun"},{"key":"2026043013120627800_ciaf648-B6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14712598.2022.2078160","article-title":"Therapeutic monoclonal antibodies for COVID-19 management: an update","volume":"22","author":"Chavda","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026043013120627800_ciaf648-B7","doi-asserted-by":"crossref","first-page":"e1017","DOI":"10.1016\/S2214-109X(21)00140-6","article-title":"Operation Warp Speed: implications for global vaccine security","volume":"9","author":"Kim","year":"2021","journal-title":"Lancet Global Health"},{"key":"2026043013120627800_ciaf648-B8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)02344-8","article-title":"Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability","volume":"399","author":"Moon","year":"2022","journal-title":"The Lancet"},{"key":"2026043013120627800_ciaf648-B9","author":"ACT-A tools funding commitment tracker"},{"key":"2026043013120627800_ciaf648-B10"},{"key":"2026043013120627800_ciaf648-B11","author":"ECA"},{"key":"2026043013120627800_ciaf648-B12","author":"European Commission"},{"key":"2026043013120627800_ciaf648-B13","author":"UK parliament"},{"key":"2026043013120627800_ciaf648-B14"},{"key":"2026043013120627800_ciaf648-B15","author":"WHO"},{"key":"2026043013120627800_ciaf648-B16","doi-asserted-by":"crossref","first-page":"m3379","DOI":"10.1136\/bmj.m3379","article-title":"A living WHO guideline on drugs for covid-19","volume":"370","author":"Agarwal","year":"2020","journal-title":"BMJ"},{"key":"2026043013120627800_ciaf648-B17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2026043013120627800_ciaf648-B18","doi-asserted-by":"crossref","first-page":"e252223","DOI":"10.1001\/jamahealthforum.2025.2223","article-title":"Global estimates of lives and life-years saved by COVID-19 vaccination during 2020\u20132024","volume":"6","author":"Ioannidis","year":"2025","journal-title":"JAMA Health Forum"},{"key":"2026043013120627800_ciaf648-B19","author":"WHO"},{"key":"2026043013120627800_ciaf648-B20","doi-asserted-by":"crossref","first-page":"e4223","DOI":"10.1093\/cid\/ciaa1866","article-title":"Reinfection with SARS-CoV-2: implications for vaccines","volume":"73","author":"Cohen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026043013120627800_ciaf648-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2022.04.001","article-title":"High-cited favorable studies for COVID-19 treatments ineffective in large trials","volume":"148","author":"Ioannidis","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"2026043013120627800_ciaf648-B22","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.chom.2023.05.012","article-title":"Antiviral strategies for epidemic and pandemic preparedness","volume":"31","author":"Jochmans","year":"2023","journal-title":"Cell Host & Microbe"},{"key":"2026043013120627800_ciaf648-B23","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1038\/s41598-025-89043-8","article-title":"Joint analysis of time-varying effect of vaccine and antiviral drug for preventing severe complications and mortality","volume":"15","author":"Jiang","year":"2025","journal-title":"Sci Rep"},{"key":"2026043013120627800_ciaf648-B24","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/21645515.2018.1445446","article-title":"Seasonal influenza vaccine in immunocompromised persons","volume":"14","author":"Bosaeed","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013120627800_ciaf648-B25","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/ijms26041481","article-title":"Potential broad-Spectrum antiviral agents: a key arsenal against newly emerging and reemerging respiratory RNA viruses","volume":"26","author":"Luong","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026043013120627800_ciaf648-B26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41579-024-01036-y","article-title":"COVID-19 drug discovery and treatment options","volume":"22","author":"Chan","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"2026043013120627800_ciaf648-B27","doi-asserted-by":"crossref","first-page":"10113","DOI":"10.1016\/j.eclinm.2021.101113","article-title":"Attitudes, acceptance and hesitancy among the general population worldwide to receive the COVID-19 vaccines and their contributing factors: a systematic review","volume":"40","author":"Cascini","year":"2021","journal-title":"eClinicalMedicine"},{"key":"2026043013120627800_ciaf648-B28","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2026043013120627800_ciaf648-B29","doi-asserted-by":"crossref","first-page":"2347019","DOI":"10.1080\/21645515.2024.2347019","article-title":"Pandemic preparedness through vaccine development for avian influenza viruses","volume":"20","author":"Cargnin Faccin","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"2026043013120627800_ciaf648-B30","first-page":"100389","article-title":"The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: a modelling study","volume":"21","author":"Leung","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"key":"2026043013120627800_ciaf648-B31","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s13063-024-08273-9","article-title":"Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England","volume":"25","author":"Pessoa-Amorim","year":"2024","journal-title":"Trials"},{"key":"2026043013120627800_ciaf648-B32","doi-asserted-by":"crossref","first-page":"eadd3055","DOI":"10.1126\/scitranslmed.add3055","article-title":"Pandemic preparedness strategies must go beyond vaccines","volume":"15","author":"Gupta","year":"2023","journal-title":"Sci Transl Med"},{"key":"2026043013120627800_ciaf648-B33","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s40471-023-00336-w","article-title":"A new paradigm for pandemic preparedness","volume":"10","author":"Fefferman","year":"2023","journal-title":"Curr Epidemiol Rep"},{"key":"2026043013120627800_ciaf648-B34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"key":"2026043013120627800_ciaf648-B35","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(23)00015-6","article-title":"Stopping epidemics when and where they occur","volume":"401","author":"Torreele","year":"2023","journal-title":"Lancet"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf648\/65511754\/ciaf648.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/727\/65511754\/ciaf648.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/727\/65511754\/ciaf648.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:12:14Z","timestamp":1777569134000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/727\/8342821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,25]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf648","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,11,25]]}}}